On October 18, 2016 Otsuka Pharmaceutical Co., Ltd., which is active in the discovery of new medicines in the fields of cancer and central nervous system diseases reported positive phase III trials results for a drug compound in development by Novartis related to its subsidiary Astex Pharmaceuticals (Press release, Otsuka, OCT 18, 2016, View Source [SID1234515912]). Schedule your 30 min Free 1stOncology Demo! Positive clinical trial results on ribociclib (LEE011) plus letrozole as first-line treatment for advanced or metastatic breast cancer, compared to letrozole alone, were presented by Novartis at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2016. (The contents of this press release were announced earlier by Novartis in an October 8 press release. See the press release on the trial results including full safety and efficacy data here.)
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the trial (MONALEESA-2 study), patients with HR+ (hormone receptor positive)/HER2- (human epidermal growth factor receptor 2-negative), advanced or metastatic breast cancer were assigned to treatment with ribociclib (LEE011) and letrozole or to the standard of care: letrozole alone. Progression-free survival (the length of time during which cancer does not progress) was significantly extended in the experimental group treated with ribociclib plus letrozole. Trial results were published simultaneously in an online article in The New England Journal of Medicine.
Ribociclib (LEE011) was developed by the Novartis Institutes for BioMedical Research under a research collaboration with Astex Pharmaceuticals.
Otsuka’s subsidiary Astex undertakes drug discovery in the U.K. directed at unmet medical needs in the field of oncology and diseases of the CNS, thereby contributing to the lives of patients and their families.